Cipla's stock surged following Citi's 'Buy' rating and a 90-day Positive Catalyst Watch. The brokerage anticipates growth from potential US...

As the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...

Indian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...

Corporate India's March 2026 quarter results showed a mixed performance. While revenues grew strongly, input cost inflation and a weaker ru...

Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...

BSE Sensex and Nifty 50 extended gains for a second session, led by banking, metal and pharma stocks despite IT weakness. Analysts flagged ...

NLC India shares rose to a record high on Thursday after the company posted a 189% YoY surge in Q4 net profit to Rs 1,394 crore. Revenue ro...

Cipla shares surged on Thursday, extending gains to nearly 11% in two sessions, after several brokerages turned bullish on the stock despit...

Pharma major Cipla announced a significant 55% drop in its net profit for the March quarter. Total income also saw a 3% decrease. For the f...

Cipla's fourth-quarter net profit saw a significant drop of 55 percent year-on-year. For the full financial year, the company's profit also...

TVS Motor Q4 Results: TVS Motor posted a strong Q4FY26 with net profit up 19% to Rs 772 crore and revenue rising 30% to Rs 15,053 crore. Ov...

Cipla Ltd announced a significant 55% year-on-year drop in its consolidated net profit for the fourth quarter, reaching Rs 555 crore. This ...

Markets faced selling pressure on Tuesday due to weak global cues and macroeconomic concerns, with the Nifty approaching support at 23,150....

Indian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...

Cipla Ltd reported a record second-quarter revenue exceeding Rs 7,500 crore, driven by strong demand for its respiratory drugs and a growin...

Drug major Cipla today reported a consolidated net profit of Rs 358.06 crore for the second quarter ended September 30, 2013.

March 2010 Q results of Dr Reddy’s Labs (DRL) & Cipla were below expectations. While DRL looks to be steadily clawing back on the path to r...